SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price o ...

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company's sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging ("SNMMI") Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Comp ...

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company's sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging ("SNMMI") Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CATX NYSE American LLC Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period the registrant was required to file such reports), and (2) has be ...

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. Perspective Therape ...

Clinical Development - As of May 15, 2024, the Company initiated dosing of nine patients in Cohorts 1 and 2 of its Phase 1/2a study of [212Pb]VMT-α-NET, with seven patients receiving 185 MBq (5 mCi) in Cohort 2[2] - The Company is collaborating with thought leaders on investigator-initiated studies to further elucidate the clinical profile of [212Pb]VMT-α-NET[5] - The Company entered a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with nivolumab in patients with melanoma[15] - The company expects to submit the VMT01 study amendment in Q2 2024 and anticipates the U.S. Phase I study for PSV359 to commence in 2025[48] - The company aims to file an IND for PSV359 in late 2024, with research and development expenses expected to increase as it invests in new drug development[48] Financial Performance - Net loss for the three months ended March 31, 2024, was $12.3 million, or $0.02 loss per basic and diluted share, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2023[44] - Grant revenue for the three months ended March 31, 2024, was $0.3 million, an increase of approximately 50% compared to $0.2 million for the same period in 2023[32] - Grant revenue for Q1 2024 was $325,000, an increase of 39.5% compared to $233,000 in Q1 2023[51] - The net loss from continuing operations for Q1 2024 was $11,825,000, compared to a net loss of $9,405,000 in Q1 2023, representing a 25.7% increase in losses[51] - The company reported a basic and diluted loss per share of $0.02 for Q1 2024, compared to a loss of $0.00 in Q1 2023[51] Expenses - Research and development expenses increased by approximately 127% to $7.5 million for the three months ended March 31, 2024, compared to $3.3 million for the same period in 2023[42] - Research and development expenses rose to $7,452,000 in Q1 2024, up 125% from $3,309,000 in Q1 2023[51] - Total operating expenses for the quarter ended March 31, 2024, were $13.3 million, an increase of approximately 33% compared to $10.0 million for the same period in 2023[34] - Total operating expenses increased to $13,330,000 in Q1 2024, compared to $9,994,000 in Q1 2023, reflecting a 33.3% rise[51] Cash and Assets - Cash, cash equivalents, and short-term investments as of March 31, 2024, were $180.6 million, compared to $9.2 million on December 31, 2023[45] - Cash, cash equivalents, and short-term investments increased significantly to $180,648,000 as of March 31, 2024, from $9,238,000 as of December 31, 2023[55] - Total assets grew to $278,286,000 as of March 31, 2024, compared to $97,891,000 at the end of 2023[55] Strategic Developments - The Company closed the acquisition of a state-of-the-art radiopharmaceutical manufacturing facility in Somerset, New Jersey, with filing expected in the second half of 2024[29] - The company is developing a proprietary 212Pb generator to secure key isotopes for clinical trials and commercial operations[52] - The Company raised $177.2 million in gross proceeds through various financing transactions and an additional $49.5 million subsequent to March 31, 2024, under its ATM Agreement[9]

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthru ...

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthrup ...

Table of Contents Expand the potential of its program candidates in additional indications and as combination therapies in current and additional indications. SSTR2, the molecular target of [212Pb]VMT-α-NET, is overexpressed in a number of cancers that are not classified as NETs, including meningioma and neuroblastoma. Both of these cancers can be difficult to treat when advanced and inoperable, but this is especially true for advanced neuroblastoma, a rare and orphan pediatric disease that is one of the mo ...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE – March 28, 2024 – Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. "We made tremendous progress during 2023 in building a fully integrated radiopharmaceu ...